Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical Trials
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hoang, Tung | - |
dc.contributor.author | Myung, Seung-Kwon | - |
dc.contributor.author | Pham, Thu Thi | - |
dc.contributor.author | Park, Boyoung | - |
dc.date.accessioned | 2022-07-08T09:28:41Z | - |
dc.date.available | 2022-07-08T09:28:41Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2020-03 | - |
dc.identifier.issn | 2072-6694 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/146078 | - |
dc.description.abstract | This study aimed to evaluate the efficacy of anaplastic lymphoma kinase (ALK)-inhibitors in the treatment of ALK-positive non-small cell lung cancer (NSCLC) by using a meta-analysis of clinical trials. We searched PubMed, EMBASE, Cochrane Library, and Clinicaltrials.gov by using keywords related to the topic in August 2018. The pooled effect sizes were calculated based on a random-effects model. We also performed subgroup meta-analysis by types of ALK inhibitors (crizotinib, ceritinib, and alectinib). A total of 20 clinical trials with 10 single-arm trials and 10 double-arm trials were included in the final meta-analysis. The median overall survival (OS), progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), 1 year survival rate, and 2 year survival rate were 19.14 months, 8.47 months, 62%, 78%, 74%, and 62%, respectively. ALK inhibitors showed a significantly superior efficacy compared with chemotherapy (hazard ratio (HR) for OS, 0.83; HR for PFS, 0.43; rate difference (RD) for ORR, 0.23; and RD for DCR, 0.10). The current meta-analysis of clinical trials showed the significant efficacy of ALK inhibitors in the treatment of ALK-positive NSCLC. Further head-to-head trials are needed to compare their efficacy with other types of NSCLC treatment regimens. PROSPERO registration: CRD42018085987. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.title | Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical Trials | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Boyoung | - |
dc.identifier.doi | 10.3390/cancers12030526 | - |
dc.identifier.scopusid | 2-s2.0-85079866640 | - |
dc.identifier.wosid | 000530232300002 | - |
dc.identifier.bibliographicCitation | CANCERS, v.12, no.3, pp.1 - 14 | - |
dc.relation.isPartOf | CANCERS | - |
dc.citation.title | CANCERS | - |
dc.citation.volume | 12 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 14 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | PROGRESSION-FREE SURVIVAL | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | PLUS NSCLC | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | BIAS | - |
dc.subject.keywordAuthor | ALK inhibitors | - |
dc.subject.keywordAuthor | non-small cell lung cancer | - |
dc.subject.keywordAuthor | crizotinib | - |
dc.subject.keywordAuthor | ceritinib | - |
dc.subject.keywordAuthor | alectinib | - |
dc.identifier.url | https://www.mdpi.com/2072-6694/12/3/526 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.